Newsbenzinga
AstraZeneca Invests in Summit Therapeutics after Year of Speculation
· Published
Article summary
AstraZeneca buys $2 billion in Summit Therapeutics equity to test ivonescimab with ADCs, providing capital.
An excerpt from the original article.
Comments —
Loading comments…